Safety of AlloPBPCT donors: Biometrical considerations on monitoring long term risks

Bone Marrow Transplantation

Volumn 17, Issue SUPPL. 2, 1996, Pages

  Hasenclever, Dirk ^a   Sextro, Michael ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOGRAFT; BIOMETRY; CANCER RISK; CONFERENCE PAPER; DONOR; DRUG SAFETY; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTERNATIONAL COOPERATION; LEUKEMIA; PRIORITY JOURNAL; SAFETY; STEM CELL TRANSPLANTATION;

GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA; LYMPHOCYTE COUNT; RISK FACTORS; SAFETY; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 0029865189     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Bensinger WI, Price TH, Dale DC, Appelbaum FR, Clift R, Lilleby K, Williams B, Storb R, Thomas ED, Buckner CD (1993): The Effects of Daily Recombinant Human Granulocyte Colony-Stimulating Factor on Normal Granulocyte Donors Undergoing Leukapheresis. Blood 81,7:1883-1888
2. Donadieu J (1993): A propos du risque leucémogène lors de l'utilisation au long cours du G-CSF dans les neutropénies constitutionelles. Arch Fr Pediatr 50:827
3. Gabrilove J, Golde DW (1993): Haemopoietic growth factors EN: DeVita VT, Hellman S., Rosenberg SA.(eds): Cancer. Principles & Practice of Oncology, 4th Edition. Philadelphia 1993
4. Henry-Amar M, Aeppli DM, Anderson J, Ashley S, Bonichon F, Cox RS, Dahlberg SJ, Deboer G, Dixon DO, Gobbi PG, Gregory W, Hasenclever D, Loeffler M, Pompe Kirn V, Santarelli MT, Specht L, Swindell R, Vaughan Hudson B: Workshop statistical report. IN: Somers R, Henry-Amar M, Meerwaldt JK, Carde P (Eds): Treatment strategy in Hodgkin's disease. ENSERM Vol. 196 John Libbey Eurotext (1990) 169-418
5. Imashuku S, Hibi S, Kataoka-Morimoto Y, Yoshihara T, Ikcushima S, Morioka Y, Todo S (1995): Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration. Br J Haematol 89,1: 188-90
6. Izumi T, Muroi K, Takatoku M, Imagawa S, Hatake K, Miura Y (1994): Development of acute myeloblastic leukaemia in a case of aplastic anaemia treated with granulocyte colony-stimulating factor. Br J Haematol 87,3: 666-668
7. Kondo S, Okamura S, Asano Y, Harada M, Niho Y (1991): Human granulocyte colony-stimulating factor receptors in acute myelogenous leukemia. Eur J Haematol 46,4: 223-230
8. Loeffler M, Tsodikov AD, Yakovlev AYu (to appear 1996): Assessing the risk of secondary leukemia in patients treated for Hodgkin's disease. Preprint
9. Omori F., Okamura S., Shimoda K., Otsuka T., Harada M., Niho Y. (1992): Levels of human serum granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor under pathological conditions. Biotherapy 4: 147-153
10. Pauksen K., Elfman L., Ulfgren A-K., Venge P. (1994): Serum Levels of granulocyte-colony stimulating factor (G-CSF) in bacterial and viral infections, and in atypical pneumonia. British Journal of Haematology, 88: 256-260
11. Russell NH (1992): Autocrine growth factors and haemopoiesis. Blood Rev 6,3: 146-156
12. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Löffler H, Hunter A, Russel NH (1995): Primary Transplantation of Allogeneic Peripheral Blood Progenitor Cells mobilised by Filgrastim (G-CSF). Blood in press
13. Vincent et al. (1994): Pharmacology of Filgrastim IN: Morstyn G., Dexter T.M. (eds.): Filgrastim (r-metHuG-CSF) in clinical practice. New York 1994
14. Wong WY, Williams D, Slovak ML, Charak B, Mazumder A, Snyder D, Powars DR, Brynes RK(1993): Terminal acute myelogenous leukemia in a patient with congenital agranulocytosis. Am J Hematol43,2: 133-138